Context Therapeutics (CNTX) News
NASDAQ: CNTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CNTX news summary
We found 3 recent headlines mentioning Context Therapeutics (CNTX): 0 in the past week and 1 in the past 30 days, most often from Nasdaq, GlobeNewswire. CNTX is making an outsized move today, down 5.10% at $0.16, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress", was published by GlobeNewswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Context Therapeutics headlines
- Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline ProgressCTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 monthsGlobeNewswire
- New Strong Sell Stocks for October 15thCDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.NasdaqCDZI, CNTX, CNSY
- New Strong Sell Stocks for October 13thATS, CANG and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2026.NasdaqCANG, CNTX, ATS